A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 232 participants.
Also called NCT03320031
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 232 participants
- Sponsor
- Yanbing Li
- Registry
-
NCT03320031
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03320031. Randomized; no masking; primary purpose treatment. Start 2017-06-03 (actual); primary completion 2019-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Peritoneal Dialysis
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Humalog Mix 75/25
- Lead sponsor
- Yanbing Li
Record details
- Record id
cardio:ct-nct03320031- Content hash
2d2532a1fb02b3f52061467314a13331ee852102de93ed5a44f9fcf66fbea914